Table 3.

Factors related to ORR at first month

Items	logistic regression analysis
	P value	OR	95% CI
			Lower	Higher
Univariate logistic regression
Therapy
Apatinib	Ref
Apatinib plus cTACE	0.105	4.500	0.730	27.739
Apatinib plus DEB-TACE	0.036	8.250	1.154	59.003
Age (>60 years vs. ≤60 years)	0.600	1.481	0.341	6.425
Gender (male vs. female)	0.556	0.625	0.131	2.984
Wight (>60 kg vs. ≤60 kg)	0.633	0.705	0.168	2.955
HBV (positive vs. negative)	0.600	1.481	0.341	6.425
ECOG score (2 vs. 1)	0.028	0.167	0.034	0.826
Child-Pugh stage (B vs. A)	0.232	2.500	0.556	11.250
Number of intrahepatic tumors (>3 vs. ≤3)	0.130	0.263	0.047	1.481
Macroscopic vascular invasion (yes vs. no)	0.263	2.700	0.474	15.396
Tumor size (>5 cm vs. ≤5 cm)	0.494	0.540	0.092	3.159
Lymph node metastasis (yes vs. no)	0.999	0.000	0.000	-
Distant metastasis (yes vs. no)	0.263	0.370	0.065	2.112
TNM stage (IV vs. III)	0.417	0.525	0.111	2.487
CA199￡ (abnormal vs. normal)	0.766	0.800	0.184	3.487
Bile duct dilatation (yes vs. no)	0.215	2.667	0.566	12.557
Biliary drainage (yes vs. no)	0.657	1.500	0.251	8.977
Previous therapy (yes vs. no)	0.671	0.721	0.159	3.266
Forward stepwise multivariate logistic regression
Therapy
Apatinib	Ref
Apatinib plus cTACE	0.098	5.861	0.720	47.713
Apatinib plus DEB-TACE	0.027	14.963	1.371	163.356
ECOG score (2 vs. 1)	0.023	0.100	0.014	0.729

ORR, objective response; OR, odds ratio; CI, confidence interval; Ref, reference; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; HBV, hepatitis B virus; ECOG, Eastern Co-operative Oncology Group; CA199, carbohydrate antigen 199.

^￡normal: CA199 level ≤27.0 U/mL, abnormal: CA199 level >27.0 U/mL.